Citizens Jmp Downgrades Vigil Neuroscience (NASDAQ:VIGL) to Hold

Vigil Neuroscience (NASDAQ:VIGL) was downgraded by Citizens Jmp from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

VIGL has been the topic of several other reports. Citigroup cut Vigil Neuroscience to a “market perform” rating in a report on Thursday. JMP Securities restated a “market perform” rating on shares of Vigil Neuroscience in a report on Thursday. Wedbush downgraded Vigil Neuroscience from a “strong-buy” rating to a “hold” rating and reduced their price objective for the stock from $13.00 to $8.00 in a research note on Thursday. Guggenheim set a $8.00 price objective on Vigil Neuroscience and gave the stock a “neutral” rating in a report on Thursday. Finally, HC Wainwright lowered their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 14th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $13.00.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock opened at $7.89 on Thursday. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95. The firm’s 50 day moving average price is $2.19 and its 200-day moving average price is $2.30. The stock has a market cap of $368.24 million, a P/E ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL) last posted its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, equities analysts expect that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. abrdn plc increased its stake in Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after acquiring an additional 293,461 shares during the last quarter. Blair William & Co. IL purchased a new position in shares of Vigil Neuroscience in the 4th quarter worth approximately $551,000. Renaissance Technologies LLC increased its position in shares of Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock valued at $624,000 after purchasing an additional 321,300 shares during the last quarter. Barclays PLC increased its position in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after purchasing an additional 19,436 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Vigil Neuroscience by 85.3% during the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company’s stock valued at $454,000 after buying an additional 122,853 shares during the period. Institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.